Risk Factor Analysis for Occurrence of Linezolid-Resistant Bacteria in the Digestive and Respiratory Tract of Food-Producing Animals in Belgium: A Pilot Study.

One Health antimicrobial resistance antimicrobial use florfenicol use linezolid resistance risk factors

Journal

Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404

Informations de publication

Date de publication:
29 Jul 2024
Historique:
received: 08 07 2024
revised: 23 07 2024
accepted: 24 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

Linezolid is a critically important antimicrobial used in human medicine. While linezolid is not licensed for food-producing animals, the veterinary use of other antimicrobials, such as phenicols (e.g., florfenicol), could cross/co-select for linezolid-resistant (LR) bacteria. Such LR strains pose a great concern for public health due to their potential transfer between animals and humans. This study explored possible associations between epidemiological risk factors, including phenicol use, and the occurrence of LR bacteria, such as enterococci and staphylococci, in poultry, pigs, and veal calves in Belgium. Florfenicol use significantly increased the likelihood of harboring LR bacteria in veal calves, sows, and fattening pigs, particularly for the digestive tract (odds ratio (OR): [3.19-5.29]) and the respiratory tract (OR: [6.11-9.09]). LR strains from feces from fattening pigs were significantly associated with production type (OR: [3.31-44.14]) and the presence of other animal species (OR: 0.41). The occurrence of LR strains in the respiratory tract from sows was also significantly associated with using antimicrobials other than florfenicol (OR: 10.07) and purchasing animals (OR: 7.28). Our study highlights the potential risks of using certain veterinary antimicrobials, such as florfenicol, in food-producing animals and emphasizes the need for responsible antimicrobial use to safeguard both animal and public health.

Identifiants

pubmed: 39200007
pii: antibiotics13080707
doi: 10.3390/antibiotics13080707
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : THE EUROPEAN UNION'S HORIZON2020 RESEARCH AND INNOVATION PROGRAMME
ID : 773830: One Health European Joint Programme
Organisme : Sciensano
ID : Own funding

Auteurs

Michèle Driesen (M)

Coordination of Veterinary Activities and Veterinary Epidemiology, Department of Infectious Diseases in Animals, Sciensano, 1050 Brussels, Belgium.

Michaël Timmermans (M)

Veterinary Bacteriology, Department of Infectious Diseases in Animals, Sciensano, 1050 Brussels, Belgium.

Mickaël Cargnel (M)

Coordination of Veterinary Activities and Veterinary Epidemiology, Department of Infectious Diseases in Animals, Sciensano, 1050 Brussels, Belgium.

Xavier Simons (X)

Coordination of Veterinary Activities and Veterinary Epidemiology, Department of Infectious Diseases in Animals, Sciensano, 1050 Brussels, Belgium.

Maria-Eleni Filippitzi (ME)

Laboratory of Animal Health Economics, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.

Boudewijn Catry (B)

Healthcare-Associated Infections and Antimicrobial Resistance, Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.
Faculty of Medicine, Université Libre de Bruxelles, 1070 Brussels, Belgium.

Fabiana Dal Pozzo (F)

Center of Expertise on Antimicrobial Consumption and Resistance in Animals, 1210 Brussels, Belgium.

Wannes Vanderhaeghen (W)

Center of Expertise on Antimicrobial Consumption and Resistance in Animals, 1210 Brussels, Belgium.

Bénédicte Callens (B)

Center of Expertise on Antimicrobial Consumption and Resistance in Animals, 1210 Brussels, Belgium.

Marc Dispas (M)

Health Information, Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Cécile Boland (C)

Veterinary Bacteriology, Department of Infectious Diseases in Animals, Sciensano, 1050 Brussels, Belgium.

Classifications MeSH